| ObjectiveTo evaluate the efficacy and safety of Prostant in the treatment of chronic prostatitis.MethodsA randomized, double-blind, positive drug-controlled clinical trial method was applied in the study. Through clinical symptoms, signs and expressed prostate secretion (EPS) examination, 80 patients with prostatitis were recruited and randomixed into a trial group (60 cases) and a control group (20 cases). After screening, treatment and follow-up, in the trial group and the control group, the observation on clinical efficacy and safety were evaluated, such as the clinical symptoms, signs, EPS examination, the national institute health-chronic prostatits symptom index (NIH-CPSI) and the blood routine, urine routine, stool routine, the function of liver and kindney,electrocardiograph examination and the side effects.ResultsAfter 4-week treatment, For different types of the two groups, the total effective rates were 74.14% in the trial group and 40.0% in the control group, the effect of the efficacy of Prostant was superior to that of wild chrysanthemum suppository(P=0.006).There was significant difference in clinical symptoms and NIH-CPSI between pre-treatment and post-treatment in the trial group and the control group (P<0.05). Though there was remarkable difference between pre-treatment and post-treatment in the white blood cell count in the EPS (P<0.01), not in difference of two groups (P=0.121). The tolerance to Prostant and wild chrysanthemum suppository showed no significant difference (P=0.269), and no serious side effects were recorded.Conclusion The Prostant is effective and safe on treating the chronic prostatitis and well deserves to be recommended in clinical practice.
|
PDF Full Text Request